Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
4.125
+0.045 (1.10%)
Jul 21, 2025, 2:22 PM - Market open
Altimmune Employees
Altimmune had 59 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
59
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$339
Profits / Employee
-$1,529,492
Market Cap
334.57M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ALT News
- 1 day ago - ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 12 days ago - Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) - GlobeNewsWire
- 23 days ago - Altimmune's Fatty Liver Candidate Faces Differentiation Doubts - Benzinga
- 24 days ago - Altimmune: Deciphering The MASH Crash (Rating Upgrade) - Seeking Alpha
- 24 days ago - Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide - Seeking Alpha
- 25 days ago - Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
- 25 days ago - Altimmune's weight-loss drug meets main goal in fatty liver disease trial - Reuters
- 25 days ago - Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH - GlobeNewsWire